Use of IL-27 agonists to increase interferon-gamma production
Provided are cytokines and methods of modulating activity of the immune system using cytokine agonists and antagonists. Also provided are methods of treatment of immune and proliferative disorders.
1. A method of increasing interferon-gamma (IFNgamma) production by a cell in vitro, comprising treating the cell with an effective amount of:
a) IL-12; and
b) IL-27 or an IL-27 hyperkine.
2. The method of claim 1 , wherein the increasing is about two-fold, about 5-fold, about 10-fold, about 20-fold, or about 50-fold greater than the expression or production level in the absence of the effective amount of IL-12 and IL-27 or IL-27 hyperkine.
3. The method of claim 1 further comprising treating with an additional cytokine.
4. The method of claim 3 , wherein the additional cytokine is:
a) IL-2;
b) IL-15;
c) IL-23; or
d) IL-18.
5. The method of claim 1 further comprising treating with two additional cytokines.
6. The method of claim 5 , wherein the two additional cytokines are:
a) IL-2 and IL-15;
b) IL-2 and IL-23;
c) IL-15 and IL-23; or
d) IL-18 and IL-2, IL-15, or IL-23.
7. The method of claim 1 further comprising treating with three additional cytokines.
8. The method of claim 7 , wherein the three additional cytokines are IL-18 and:
a) IL-2 or IL-15; and
b) IL-12 or IL-23.
9. The method of claim 1 , wherein the cell is a:
a) T cell; or
b) NK cell.